Sonnet BioTherapeutics Holdings, Inc. Common Stock
SONNSonnet BioTherapeutics Holdings, Inc. is a biotechnology company focused on developing novel therapies based on its proprietary peptide platform. The company's mission is to create targeted, effective treatments for a range of diseases, including cancers and autoimmune disorders, by leveraging innovative peptide technology to enhance drug delivery and efficacy.
Company News
Hyperliquid Strategies Inc completed a business combination with Sonnet BioTherapeutics, creating a digital asset treasury reserve company. The merged entity will trade under the ticker 'PURR' on Nasdaq and aims to provide investors exposure to the HYPE token ecosystem.
Heights Capital Management established a new $16.15 million position in ImmunityBio, buying 6,565,709 shares, representing 4.4% of its assets under management. The investment suggests potential confidence in the company's clinical-stage immunotherapy pipeline.
Sonnet BioTherapeutics, a clinical-stage oncology company, will present at the MedInvest Biotech & Pharma Conference. The company is developing immunotherapeutic drugs using its FHAB platform, with lead program SON-1010 being studied for ovarian cancer treatment in collaboration with Roche.
Sonnet (SONN) receives FDA clearance to begin clinical development for its combination therapy of SON-1010 and Roche's atezolizumab, for the potential treatment of platinum-resistant ovarian cancer.
Hot penny stocks to buy under $1 The post Best Penny Stocks to Buy Under $1? 7 To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
